Crystagen

Crystagen is a synthetic tripeptide composed of glutamic acid, aspartic acid, and proline (Glu-Asp-Pro, single-letter code EDP). It belongs to the Khavinson Cytogen class developed at the St. Petersburg Institute of Bioregulation and Gerontology. The compound was identified through epitope mapping as a principal active component within Thymalin, the thymus extract Cytomax that has the longest Russian clinical history of any Khavinson preparation.

The Khavinson bioregulator program produced two parallel compound classes. Cytomaxes are organ-specific peptide extracts containing heterogeneous mixtures of peptides up to several kDa. Cytogens are short synthetic peptides designed to reproduce single defined active sequences. For the thymus and immune system, Thymalin is the Cytomax with multiple identified active components: the Glu-Trp dipeptide Thymogen, the Lys-Glu dipeptide (Vilon), and Crystagen as the EDP tripeptide. Thymalin remains in clinical use in Russia and has accumulated decades of observational data.

Crystagen's relationship to Thymalin provides an indirect clinical pedigree. The parent Cytomax has been used in Russian medical practice since the 1980s with accumulated reports on immune normalization in elderly populations, post-illness recovery, and adjunct use in infectious disease protocols. Whether the isolated EDP tripeptide reproduces the full spectrum of Thymalin's clinical effects has not been formally demonstrated; the parent extract contains multiple potentially active components, and attributing specific effects to Crystagen alone is methodologically difficult.

The Evidence

The compound-specific evidence base consists of:

• Cell culture work documenting selective stimulation of normal lymphocyte proliferation while inhibiting growth of K-562 erythromyeloid tumor cells. The selective stimulation pattern is mechanistically distinct from broad immunostimulants.
• Aged population observational data reporting normalization of immunogram parameters in approximately 82 percent of elderly patients after Crystagen courses, compared with approximately 56 percent in untreated comparison groups.
• Heat shock protein modulation in athletic populations reported doubled HSP gene expression and reduced respiratory infection rates during heavy training periods.
• Parent Thymalin clinical data including a randomized controlled trial of Thymalin in COVID-19 patients during the pandemic, which reported improvements in inflammatory markers and clinical outcomes; the trial does not isolate Crystagen-specific effects.

Independent Western confirmation is sparse. PubMed indexing for Crystagen specifically returns predominantly Khavinson-affiliated publications. No registered ClinicalTrials.gov trial exists for Crystagen alone as of May 2026.

Regulatory and Legal Status

FDA. No approval. Not on bulk drug substances list.

EMA. No approval. Thymalin (parent extract) is not approved in EU.

Russia. Crystagen is sold as a biologically active dietary supplement. Thymalin has Russian pharmaceutical registration.

WADA. Not on 2026 Prohibited List.

The proposed mechanism follows the Khavinson short-peptide bioregulation framework with immune-system tissue specificity.

Cellular entry and nuclear binding. EDP is hypothesized to enter immune cells (thymocytes, peripheral T cells, B cells, natural killer cells) through peptide transporters, reach the nucleus, and modulate gene expression. The Khavinson model treats this as the basis for selective immunomodulation.

Proposed downstream effects. Cell-culture and animal studies have reported:

• Selective stimulation of normal lymphocyte proliferation
• Inhibition of K-562 tumor cell line growth (selective effect on transformed cells)
• Modulation of heat shock protein gene expression
• Effects on cytokine production patterns including IL-2 and IL-6
• Modulation of T-cell differentiation and apoptosis
• Possible support of thymic epithelial cell function

The proposed mechanism for Thymalin (and by inference Crystagen) emphasizes restoration of thymic function in age-related thymic involution. Thymic atrophy with aging contributes to reduced naive T-cell output and broader immunosenescence; agents that support thymic function could partially address this aging process.

Comparison with established immune mechanisms. Pharmaceutical immunomodulators work through well-characterized mechanisms: corticosteroids (broad transcriptional effects), calcineurin inhibitors (cyclosporine, tacrolimus), JAK inhibitors, mTOR inhibitors, anti-cytokine antibodies. The Khavinson proposed mechanism (selective nuclear peptide-DNA interaction in immune cells) is not validated by independent transcriptomic studies and is not a class targeted by approved pharmaceuticals.

Pharmacokinetics. Oral and sublingual tripeptides face gut hydrolysis. The Khavinson framework proposes signaling at the gut-mucosa interface propagated systemically. Direct measurement of intact Crystagen in plasma after administration has not been published.

Human pharmacokinetic data is not published.

Russian-institution observational data and laboratory studies report:

• Normalization of immunogram parameters in elderly populations
• Reduction in respiratory infection frequency in athletic and elderly populations
• Modulation of heat shock protein expression markers
• Subjective improvement in resistance to viral and bacterial infections
• Adjunct effects in chronic infection protocols
• Possible benefit in post-chemotherapy immune recovery

Research-chemical user reports describe subjective improvements in cold and flu resistance and general energy. Reports are uncontrolled and not verified for vial identity. The immune-effect claims are particularly difficult to evaluate in uncontrolled use because most users have low baseline infection frequency, making improvement difficult to detect or attribute.

No standardized human dosing protocol supported by independent pharmacokinetic data exists for Crystagen.

Russian retail Crystagen is dosed as oral capsules or sublingual liquid containing approximately 10 mg of active peptide. Standard Russian-protocol dosing is 1 to 2 doses once or twice daily during meals for a 30-day course, repeated 2 to 3 times per year.

Research-chemical Crystagen is sold as lyophilized powder in 20 mg vials. Subcutaneous protocols typically use 100 to 500 mcg per day over 10 to 20 day cycles. These doses are extrapolated from generic Khavinson recommendations and lack Crystagen-specific human pharmacokinetic support.

The Khavinson bioregulator class has a benign published adverse-event profile. Russian manufacturer documentation lists individual intolerance, pregnancy, lactation, and active autoimmune flares as contraindications. The autoimmune-flare contraindication is mechanism-relevant: an immune-stimulating peptide could theoretically exacerbate active autoimmune disease activity.

The constituent amino acids (glutamic acid, aspartic acid, proline) are common dietary amino acids. Tripeptide doses at the microgram-to-milligram level fall within typical dietary peptide exposure.

Long-term human safety data with controlled endpoints does not exist. Theoretical concerns specific to chronic immunomodulation:

• Effects in patients with active autoimmune disease (RA, lupus, IBD, MS) have not been evaluated; theoretical risk of disease flare
• Drug-drug interactions with immunosuppressants (corticosteroids, calcineurin inhibitors, biologics) have not been studied
• Effects in patients with hematologic malignancies have not been evaluated; the K-562 tumor inhibition reported in cell culture does not generalize to all cancer types
• Effects on transplant patients on immunosuppression have not been characterized

For users with diagnosed immune-system disease, the relevant safety consideration is not Crystagen's direct toxicity but the risk of substituting unproven supplements for evidence-based therapy.

Within the Khavinson system, Crystagen is the synthetic Cytogen for the immune axis, derived by epitope mapping from the Thymalin Cytomax. The standard Cytogen-then-Cytomax sequence pairs Crystagen with Thymalin in extended protocols.

For broader immune-system bioregulator stacks, Crystagen combines with:

• Thymalin (Cytomax counterpart)
• Thymogen (Glu-Trp dipeptide, separately marketed Cytogen also from Thymalin)
• Thymosin Alpha-1 (28-amino-acid peptide with established receptor-mediated mechanism, approved in over 35 countries for various indications)
• Vilon (Lys-Glu dipeptide for general immune-aging support)

For broader geroprotective protocols, Crystagen joins Epitalon (pineal Cytogen) and other organ-specific bioregulators.

External comparators in clinical immunology have substantial evidence bases for specific indications:

• Vaccines for primary prevention of specific infections (substantial Phase 3 evidence across decades)
• Antibiotics, antivirals, antifungals for specific active infections
• Disease-modifying antirheumatic drugs (DMARDs) for autoimmune disease management
• Biologic immunomodulators (anti-TNF, anti-IL-17, anti-IL-6, JAK inhibitors) for specific autoimmune conditions
• Hematopoietic growth factors (filgrastim, pegfilgrastim) for chemotherapy-induced neutropenia

Crystagen has no comparable evidence base for any specific immune-system indication. Its role, if any, is as an investigational supplement in research contexts rather than as therapy for diagnosed disease.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.